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INTRODUCTION
Signal transducer and activator of transcription (STAT) proteins are a family of transcription factors implicated in growth factors and cytokines signalling [1] . In the canonical model of STATs signalling, singles monomers are normally sequestered in the cytoplasm in an inactive form. Their activation is initiated by tyrosine phosphorylation, usually mediated by the binding of cytokines or growth factors to their membrane receptors and/or by intracellular oncogenic tyrosine kinases, such as JAKs and Src. Upon cytoplasmic tyrosine phosphorylation, two STAT monomers dimerize, translocate to the nucleus and bind to specific promoter sequences, thereby regulating gene expression [1] . Under physiological conditions, every phospho-STAT protein has a limited activation period that typically lasts from a few minutes to several hours, while persistent activation of STAT proteins, in particular STAT3 and STAT5, is observed in a wide variety of cancers, including breast cancer [2] .
STAT3 is implicated in a vast range of physiological processes including cellular proliferation, differentiation, inflammation and immune response [3] [4] [5] [6] , but can also act as an oncogene to induce cellular transformation and tumorigenesis [7] . Indeed, persistently tyrosine phosphorylated STAT3 has been reported in nearly 70% of haematological and solid tumors [8] . Because of its wide range of functions, STAT3 is involved in many aspects of carcinogenesis such as proliferation, survival, angiogenesis and metastasis [9, 10] and can also contribute to tumor escape from immune surveillance [11, 12] and to the establishment of tumor drug resistance [13, 14] .
Consistently, persistent activation of Stat3, has been reported in human breast carcinoma cell lines but not in mammary epithelial cell lines derived from non-malignant tissues [15, 16] . signalling and are more sensitive to its inhibition than normal cells [8, 17] . Indeed, direct inhibition of STAT3 activities by multiple means, such as overexpression of dominant negative isoforms [18] , antisense oligonucleotides [19] , RNAi [20, 21] or small drug inhibitors [22] results in growth inhibition and induces apoptosis in breast cancer and other model systems [23] . The direct implication of Stat3 as a promoter of breast tumor growth and progression is further supported by the observation that breast tumor sample show increased Stat3 activity compared to matched non neoplastic tissues, but decreased in samples from patients with a complete pathological response to doxorubicin/docetaxel treatment compared to partial responders [24] .
Inihibition of STAT3 activity therefore represents a promising approach in the treatment of breast cancer. Redirection of STAT3 alternative splicing therefore presents an attractive way to eliminate the tumorigenic STAT3 alpha variant while simultaneously inducing the generation of the STAT3beta variant, which possesses marked anti-tumoral properties.
In the previous CDMRP-BCRP-funded study (BC074961, Modulation of Stat3
Alternative Splicing in Breast Cancer), we induced the STAT3beta isoform using an antisense approach, where modified oligonucleotides were very specifically targeted to splicing regulatory elements to either inhibit or promote the usage of splicing sites [25] . Use of antisense compounds is a wellestablished approach for gene expression regulation [26] targets and are highly resistant to nucleases and proteases. We had previously developed chimeric compounds that are coupling to the antisense moiety of a peptide (RS-rich) that mimics the action of the "RS domain", the 'activation domain' of splicing factors [27] . In addition,
Arginine-rich peptides share structural similarities to translocating peptides (like TAT) that are able to mediate free-uptake of bound cargo into cells. In addition, we have also used a formulation of the compounds (vivo-morpholino) where a cationic dendrimer is coupled to the oligonucleotide instead of the peptide. This variant was originally developed by Gene-tool for in vivo treatments.
We thus used splicing redirection compounds to induce a switch from the alpha to the STAT3beta isoform ( Figure 3 ).
To be able to compare the effect of the beta switch to those of a STAT3 knock-down, we adapted the splicing redirection approach to cause a total knock-down by inducing an early splicing shift of a constitutive exon, which leads to a frameshift, a Premature Termination Codon (PTC) and eventually to degradation of the mRNA by nonsense-mediated decay (NMD). The resulting fsd-NMD (forced splice-dependent NMD) was used to completely knock- by a mechanism different than a straight dominant negative effect.
Indeed, we found that the alpha-to-beta switch activates a specific transcription program that includes downregulation of survival factors, including LEDGF, PCAF, Cyclin C and
Stat1beta. Next, we tested whether the splicing redirection compounds also possess antitumor activity in vivo. The beta-switching compound ST2 and the knock-down compound ST6
were injected intratumorally in athymic mice carrying 435s-derived xenograft tumors [25] . The switch to beta was associated to a full regression of the tumors providing the first evidence that modulation of a single splicing event can have anti-tumoral properties. On the other hand, knock-down of total STAT3 didn't have a significant effect on tumor growth even if the treatment was very effective at the molecular level [25] .
BODY

Role of Stat3beta downstream effectors [Cartegni Lab]
Our previous experiments showed that reduction of STAT3a and concomitant induction of STAT3b by alternative splicing modulation can decrease cancer cell viability more efficiently than the knockdown of both STAT3 isoforms. Therefore we set out to determine which STAT3 target genes may be involved in this process.
We thus performed a screen using cDNAs from MDA-MB-435s cells treated for 4 days with ST2 (STAT3b induction), ST6 (STAT3 K.O.) or INV (control) compounds. Expression levels were analyzed by real-time PCR, using the microarray platform U133A 2.0 (Affymetrix) [25] . Whereas knocking-down both STAT3 isoforms by FSD-NMD using the ST6 compound resulted in a somewhat modest but consistent downregulation of most canonical targets analyzed (and a robust downregulation of STAT3 itself, as expected), STAT3b induction by ST2 appears to have activated a STAT3b-specific transcriptional signature [25] , indicative of the existence of different classes of target genes in terms of how they respond to STAT3a/STAT3b regulation.
Out of the panel of genes with statistically significant variation of expression levels in the microarray assay, in addition to the previously described STAT3-target interleukin 8 (IL8), five other genes were confirmed to be down-regulated both at the RNA and protein level by the switch to STAT3β, but not by the knockdown: 1.) Lens Epithelium-Derived Growth Factor (LEDGF/PSIP1, a chromatin binding protein and transcriptional co-activator; a pro-survival and growth factor) [28] ; 2.) peroxisomal biogenesis factor 1 (PEX1, part of the AAA ATPase subfamily, required for peroxisomal import) [29] ; 3.) CyclinC (CCNC, controls transcription by associating with Cdk8 and modulating RNA pol II activity and regulates G0/G1 transition) [30 Figure 5 A-E) and cell viability was measured. Individual down-regulation of PEX1, IL8 or CyclinC did not lead to an increase in cell death ( Figure 5B , D, E). On the other hand, knockdown of LEDGF ( Figure 5A ) and PCAF ( Figure 5C ), was associated to a significant decrease in cell viability.
Next we asked whether forced re-expression of the STAT3β target genes could protect from the increase in cell death induced by the α-to-β switch. We thus generated MDA- 5F, 5H-J) as treating the overexpressing cells with ST2 had no effect on their viability, unlike what observed with control cells. Taken together these data suggest that the effect of the STAT3β isoform on cell viability is likely mediated by the combined down-regulation of a specific set of target genes rather than exerted through a single major effector, in agreement with STAT3 pleiotropic functions in the pathogenesis of cancer.
In vivo treatment of stat3-dependent tumors [Cartegni lab, de Stanchina lab]
In preliminary experiments, we have tested how STAT3 alternative splicing modulation could affect tumor growth in vivo, using the ST2, ST6 and INV morpholino compounds . IHC for P-S727 (present only in STAT3α) was negative for both ST2 and ST6 treated tumors, further confirming the efficacy of these treatments at the protein level ( Figure 3G ).
Analysis of tumor sections stained for Hematoxylin and Eosin (H&E, Figure 3I ), showed that the ST2-induced splicing switch is the only treatment associated with a significant effect on tumor morphology. Of particular interest is that while STAT3 knock-down was effective at the molecular level, it did not have any notable effects on tumor morphology and growth compared to controls ( Figure 3I ).
Expression of LEDGF, Cyclin C, STAT1b and PCAF and IL8 is also inhibited in MDA-MB-435s-derived tumors in mice upon STAT3b activation, like previously described for the MDA-MB-435s cell lines. To assess whether their suppressive role in STAT3b-induced cell death also applies to in vivo tumor growth and progression when overexpressed, we started set up an in vivo system using the stable cell lines described above.
In experiments carried out in the de Stanchina lab, new baselines for tumor growth were derived in 8-10 weeks old athymic female mice, which were subcutaneously inoculated with Unfortunately there was an issue with tumor up-take, so the results of these experiments are not conclusive and will need to be repeated for statistical significance. However, our initial indications suggest that in the presence of overexpressed PCAF (and to a lesser extent STA1b) the treatment with the splice-switching ST2 vivo-morpholino compound leads to a reduction in tumor growth, although such reduction does not appear to be as effective as when PCAF is not over-expressed, in which case a full tumor regression is observed. This is important, because (if confirmed) it suggests that also in this xenograft in vivo system, PCAF plays a key role in mediating Stat3beta anti-tumoral activity.
As well as repeating and completing the experiment delineated above, we have also designed FSD-NMD morpholino compounds to knock-down endogenous PCAF expression, and to induce endogenous expression to activate STAT1b. These have now been synthesized to be tested for activity in cell lines [Cartegni lab] , Active compounds will then be used by themselves and in combination to test their anti-tumoral activity, to show that the antitumorigenic activity of the ST2 compounds is mediated by PCAF and/or STAT1b [de Stanchina lab].
In parallel, we have designed and synthesized morpholino compounds specific to either the human (ST2h) or mouse STAT3 exon 23 sequence (ST2m), which induce activation of STAT3b in either species but not in both. These have now been cross-tested in human and mouse cell lines to confirm that they can effectively and specifically activate STAT3beta in a species-specific way [Cartegni lab The only significant difference anticipated is that we will be asking for a no-cost six months extension at the end of the final funding period to compensate the delay due to the move of Dr. Cartegni's lab.
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Introduction
Cancer develops when a series of genetic changes allows a cell to break free from the normal regulatory pathways governing cell division and proliferation. Its progression is characterized by the appearance of common steps, which include sustained proliferative signaling, evasion of growth suppressors, resistance to apoptosis, activation of replicative immortality, angiogenesis, evasion from host immune response, reprogramming of metabolic pathways, genomic instability, tumor-promoting inflammation, invasion and metastasis [1, 2] . These "hallmarks of cancer" are typically driven by genetic alterations that involve gain-of-function mutations and/or overexpression of oncogenes on one hand, and loss-offunction mutations and/or silencing of tumor suppressors on the other.
Cancer therapy has traditionally been based upon the combination of chemotherapy and radiation. In recent years, the molecular characterization of cancer through genomic, transcriptome and proteomic technologies has led to the development of "targeted therapies" that specifically hit pathways essential for cancer growth and progression [3, 4] . These treatments, usually in the form of small molecule inhibitors or antibodies, have revolutionized cancer therapy and dramatically impacted survival rates [5] . However, because of the consistent emergence of resistance to conventional and targeted therapies in tumor cells, and due to the "undruggability" of many promising putative therapeutic targets, there is a persisting requirement for novel alternative drug discovery strategies.
Recent advances in nucleic acid antisensebased technology, comprising improved chemistry, pharmacology and delivery, have led to the development of a new generation of antisense oligonucleotide compounds (ASOs) with greatly improved pharmacokinetic and pharmacodynamic properties [6] . ASOs are emerging as a powerful class of drugs that can be generated against virtually any RNA --coding or non-coding--and their potential thus surpasses traditional drug discovery based on small molecule inhibitors or monoclonal antibodies. These features have led to the FDA approval of the first antisense-based drug in two decades (Mipomersen [7] ), with many more currently in clinical trial for the treatment of numerous diseases [8, 9] , including several for cancer (Table 1) .
"Antisense technology" is a broad umbrella term to indicate any approach that involves base-pairing of a compound to a target nucleic acid. It can involve diverse mechanisms of action, ranging from multiple ways to promote target RNA degradation (e.g. by RNA interference (RNAi)), to translation interference, to modulation of non-coding RNA activities and to various pre-mRNA reprogramming strategies (Box 1). In this review, we will focus on the use of synthetic ASOs to force specific changes in endogenous alternative splicing (AS) and alternative polyadenylation (APA) events and their application as a therapeutic avenue for cancer therapy.
Antisense oligonucleotides: Knockdown vs. reprogramming
In the discussion of antisense-based compounds, it is important to distinguish whether the primary goal of the treatment is to downregulate the target gene or to alter its coding potential.
Target knockdown can be achieved by various mechanisms. The most commonly used one exploits the RNAi pathway, which is activated by small interfering RNAs (siRNAs), or short hairpin RNA (shRNAs). These double-stranded RNAs are loaded into the RNA-Induced Silencing Complex (RISC) and repress expression by base-pairing with the target mRNAs and directing their cleavage and degradation [10] . SiRNAs and shRNAs have been utilized in vivo with some success, and several RNAi-based compounds are in clinical development [9, 11] . However, their current therapeutic appeal is still somewhat hindered by the requirement for complex formulations and unsatisfactory delivery in vivo, particularly to tumors.
While the lion's share of antisense applications (especially in vitro) is currently held by RNAi technologies, the use of ASOs to inhibit gene expression was pioneered in 1978 by Zamecnik and Stephenson --long before the discovery of RNAi--when ASOs complementary to a Rous sarcoma virus RNA target sequence were shown to repress viral replication [12] . Since then, multiple classes of ASOs have been developed, and while they share the defining targeting by complementary Watson-Crick base-pairing and an average length of ~20 nucleotides, they involve very different chemistries which exploit multiple underlying biological mechanisms [13] (Box 1).
"Classical" ASOs downregulate target RNA by recruiting ribonuclease H to the ASO:RNA duplex, resulting in RNAseH-mediated cleavage of the RNA moiety. They typically carry phosphorothioate (PS) backbones, the most widely used chemistry of the initial antisense technologies, and the basis for Fomivirsen, the first and -until the approval of Mipomersen-the only FDA-approved ASO drug [14] . Additional modifications coupled and/or alternative to PS have resulted in second and third generation compounds with reduced toxicity, enhanced stability in vivo, better tissue distribution and higher targeting efficiency [6, 13] . These modifications include substitutions of the ribose groups with 2'-O-Alkyl groups (2'-O-methyl [2'-OME] or 2'-Omethoxyethyl [2'-MOE]), and 2'Fluoro (2'F) or Lock Nucleic Acid (LNA) modifications, which can reduce or prevent the recruitment of RNAse H. Therefore, when the desirable outcome is the knockdown of the target gene, they are typically used in a chimeric "gapmer" context as protective wings at the sides of a core region utilizing simple DNA or other RNAseH-activating chemistries [6, 13] [6] ).
Importantly, the same modifications that do not trigger RNA degradation also allow for their usage in applications where the primary goal is not knockdown, but rather the reprogramming of target pre-mRNAs to express alternative, more desirable variants by AS or APA.
Alternative splicing and polyadenylation: One gene, many proteins
Processing of pre-mRNAs to translationcompetent mRNAs is a complex and tightly regulated multi-step process that results in the accurate removal of intronic sequences by splicing and the addition of a 5' cap and a 3' polyadenylation sequence [15] .
The choice and usage of splice sites in the premRNA can be differentially selected by AS, depending on the developmental state, tissue and cell type or in response to a variety of physiological stimuli or pathological conditions [16] . AS occurs in more than 90% of multi-exonic pre-mRNA transcripts and provides much of the proteomic diversity observed in mammalian cells [17] . AS can also downregulate expression through the introduction of premature termination codons (PTCs) by inducing frame shifts in the open reading frame. PTCs trigger the nonsense mediated decay (NMD) pathway, thus marking a transcript for degradation [18] .
Polyadenylation is a co-transcriptional nuclear process essential for efficient nuclear export, stability and translation of mRNAs [19, 20] . The process involves the endonucleolytic cleavage of the pre-mRNA, followed by the addition of a polyA tail. The specific cleavage location is controlled by cis-acting motifs, including a hexamer polyadenylation signal (PAS) and a downstream UG-rich element that aids in the recruitment of the polyadenylation machinery [20] .
Like AS, APA is prevalent and affects over 50% of human genes. APA is commonly assumed to occur 'in tandem' within a given UTR, but recent analysis has shown that alternative PAS are also frequently present in 'upstream' intronic regions [21, 22] . While tandem APA contributes mainly to the regulation of the levels of expression of one encoded product, intronic polyadenylation (IPA) also adds to the diversity of protein isoforms generated from a single gene. For example, tandem APA motifs can affect gene expression levels or transcript stability by removing/adding regulatory sequences, such as micro-RNA binding sites and/or AU-rich elements (AREs) [23] . On the other hand, the usage of IPA motifs will generate truncated mRNAs that could produce protein isoforms with potentially vastly different functions than their full-length counterparts, including dominantnegative characteristics.
Collectively AS and IPA are key molecular mechanisms for increasing the functional diversity of the human proteome, allowing the relatively small human genome (<25,000 genes) to generate an excess of 100,000 different protein isoforms [17] .
Alternative Splicing and Polyadenylation in Cancer
The alternative splicing pattern of individual premRNAs is a complex process primarily controlled by the intrinsic strength of the splice sites, by the combinational effects of competitive cis-regulatory elements within the pre-mRNA (intronic or exonic enhancers or silencers) and by the relative abundance of the trans-acting factors that recognize them (such as SR and hnRNP proteins) [24, 25] .
Given AS complexity and its pivotal role in the control of gene expression and functions, it is not surprising that many human genetic diseases are a direct consequence of aberrant splicing events. Indeed, approximately 50% of disease-associated point mutations directly affect splicing [15, 26] . These typically result from mutations that impair specific splice sites or other regulatory cis-acting elements, or that activate cryptic sites, as it can occur, for example, in β-Thalassaemia [27] .
A growing body of evidence suggests that deregulated AS is also extensively linked to the development of cancer. Cancer cells show aberrant splicing profiles, expressing isoforms that can stimulate cell proliferation, enhance survival, promote migration and invasion, influence metabolism and in general affect any aspect of tumor progression and maintenance [28] . As in genetic diseases, this can sometimes be gained through acquisition of mutations in cis-acting AS elements, like for example with splicesite mutations identified in the BRAC1 and APC tumor suppressor transcripts [29, 30] . More commonly however, the pathological splicing patterns in tumors are due to broader changes in the expression, activity and possibly specificity of regulatory trans-acting RNA binding proteins which might in part reflect regulated AS programs that are improperly activated [28, 31] or to mutations in splicing factor or core spliceosomal components [32] .
Indeed, many genes that play a key role in tumor development, invasiveness or chemo-resistance express multiple splicing isoforms, with very different and often antagonistic functions. The idea of a more direct role of splicing in tumorigenesis is also supported by the observation of oncogene-like behavior for some splicing factors, which can act as very early markers of cancer (e.g.: hnRNP A2/B21 in lung tumors [33] ), can carry frequent activating mutations (e.g.: SRSF2, SF3b1 and others in Myelodysplasia [32, 34] ) or, like SRSF1, can directly behave as powerful single-agent oncogenes in mouse models and are found to be amplified in some tumors [35, 36] . Similarly, the splicing factor hnRNP-H is up-regulated and contributes to the pathogenesis and progression of glioblastoma multiforme (GBM) by inducing oncogenic alternative splicing isoforms of Receptor d'origine nantais (RON) and Insuloma-glucagonoma protein 20 (IG20) which promote migration and survival, respectively, a switch that might reflect the re-activation of a stem-like gene expression program in the GBM cells [37] .
Although not as well characterized as AS, recent genome-wide analysis of APA also points to its de-regulation as being linked to tumorigenesis by increasing cellular proliferation and transformation. Cancer cells preferentially express oncogenes with shorter 3'UTRs, resulting in higher expression due to the loss of destabilizing and/or repressive elements from the UTR [38, 39] . Alternatively, the modulation of upstream IPA sites can generate truncated variants with tumorigenic capabilities. For example, the usage of an IPA site in Cyclin D1, which normally controls progression through the cell cycle, results in a constitutively active truncated Cyclin D1b isoform, that can lead to cellular transformation [40, 41] .
Therefore, deregulation of AS and APA/IPA can contribute to tumorigenesis due to inactivation of tumor suppressors, activation of oncogenes and generation of novel pathogenic cancer-specific isoforms.
Splice-switching oligonucleotides
Since aberrant AS and APA contribute to a multitude of different human diseases, correction of such defective pre-mRNA processing by ASOs could open an avenue for therapeutic intervention. The feasibility of this approach has been elegantly demonstrated in the development of ASO compounds for the treatment of β-Thalassaemia [42] Spinal Muscular Atrophy (SMA) [43, 44] , and Duchenne Muscular Dystrophy (DMD) [45] . Systemic delivery of splice-switching oligonucleotides (SSOs) has proven to be highly effective in pre-clinical mouse models of these genetic disorders, where a shift in endogenous splicing has been induced to correct an aberrant splicing pattern or induce expression of therapeutic splice variants, with significant physiological responses [42] [43] [44] . Furthermore, exciting early results from clinical trials of compounds directed at the treatment of DMD have shown benefit in patients, indicating that the technology is finally maturing for clinical applications [46, 47] .
The principle of inducing therapeutic variants whilst reducing deleterious ones can also be applied as a cancer therapy approach, especially since many key 'cancer genes' can generate antagonistic isoforms, which often have dominant-negative characteristics. In other words, the dual role of these proteins can be exploited by splicing re-direction approaches to manipulate their expression, in order to simultaneously eliminate the deleterious isoforms and substitute them with therapeutically desirable ones. This would be particularly effective when the targets are essential to survival of cancer, as in the case of "oncogene addiction", where cancers remain dependent upon a primary oncogenic driver activity for their continued survival and malignant progression [48] .
Here we describe some examples using this rationale to modulate AS and IPA and redirect splicing to generate antagonist or therapeutic mRNA variants that function as potential novel cancer therapies.
The anti-Warburg effect: Switching off PK-M2
Cancer cells exhibit altered metabolic pathways, to derive energy to sustain their aberrant physiology.
Normally, differentiated and nonproliferating cells generate the bulk of their energy requirements from mitochondrial oxidative phosphorylation. However, in cancer cells, energy is mainly generated through aerobic glycolysis, converting glucose to lactate, in a phenomenon known as the Warburg effect [49] .
To achieve this metabolic switch, cancer cells reprogram their energy metabolism pathways by multiple mechanisms, including by changing the splicing pattern of pyruvate kinase M (PK-M). PK-M functions as the rate limiting final step in the glycolysis pathway, converting phosphoenolpyruvate (PEP) and ADP to pyruvate and ATP [50] . AS of the PK-M gene generates two isoforms, PK-M1 and PK-M2, through the mutually exclusive usage of Exon 9 and Exon 10, respectively [51] . PK-M1 is found principally in differentiated cells, while PK-M2 is expressed in normal proliferating tissues (e.g. during embryonic development), but it is also expressed in tumor cells [52] . The regulatory role of PK-M2 in metabolism is complex, but its general role is to alter cellular glucose metabolism, increasing the availability of glycolytic metabolites that are then utilized to support proliferation and growth. In tumors, these features are essential for cancer survival and progression [52] .
The splicing regulation of the PK-M1/M2 switch involves both exonic splicing silencers (ESSs) in exon 9 and exonic splicing enhancers (ESEs) in exon 10, in conjunction with trans-acting RNA binding proteins SRSF3, PTB/nPTB, and hnRNPA1/A2, partially controlled by oncoprotein MYC [53] [54] [55] . In combination, they repress exon 9 inclusion and promote expression of the PK-M2 splice variant. 2'-MOE ASOs directed against an identified exonic splicing enhancer in exon 10 of the PK-M2 pre-mRNA were shown to inhibit exon 10 usage and re-activate PK-M1 expression by promoting exon 9 inclusion (Figure 1a ). This resulted in downregulation of PK-M2 protein expression, with a concurrent increase of the PK-M1 isoform in a panel of glioblastoma cell lines. The switch was associated with reduced viability and increased apoptosis, thus validating this approach [55] . Although further in vivo work is required, the PK-M2 to PK-M1 switchback provides a therapeutic strategy to specifically target cancer cells based on their unique metabolic signature.
From survival to apoptosis: Switching between Bcl-XL and Bcl-XS
The ability of cancer cells to escape apoptotic programmed cell death is also a key aspect of the oncogenic process and of the appearance of resistance to drugs in tumors [2] . Central to the activation of the apoptotic program are the Bcl2 family of survival proteins, which includes Bcl-X [56] . Alternative 5'ss splicing in Bcl-X exon 2 generates two isoforms with opposite functions: Bcl-XL, a wellcharacterized survival protein and the smaller Bcl-XS, a pro-apoptotic variant [57] .
Bcl-XL is up-regulated in a broad range of cancers and its over-expression is strongly associated with resistance to chemotherapy and poor clinical outcome. While Bcl-XL inhibits apoptosis through neutralizing hetero-dimerization with pro-apoptotic proteins Bak and Bax [58] , its alternative isoform, Bcl- XS induces apoptosis by directly inhibiting Bcl-XL and Bcl-2, and its levels are low in cancer cells despite the high expression of the Bcl-X gene [59] . The Bcl-XL/XS splicing regulation has been extensively investigated, and multiple controlling cis-elements and their cognate trans-acting splicing factors have been identified [60, 61] . The long recognized antagonistic functions of Bcl-XL and Bcl-XS and their central role in controlling survival of cancer cells have made them a prime target of splicing reprogramming approaches.
Several studies have employed various ASO strategies to modulate the endogenous Bcl-X AS, to effectively activate the upstream Bcl-XS 5'ss at the expense of the downstream Bcl-XL one in exon ( Figure  1b) . This switch in Bcl-X pre-mRNA processing induces apoptosis and increased in vitro chemosensitivity in lung, prostate and breast cancer cells [62] [63] [64] . Furthermore, systemic delivery of such ASOs demonstrates that switching of Bcl-X pre-mRNA can be obtained in vivo, where it reduces tumor load and metastases in a mouse model of metastatic melanoma [64] .
STAT3: the alpha to beta anti-tumorigenic switch
Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family of transcription factors, which are key down-stream effectors of gene expression following cytokine, hormone or growth factor stimulation [65] . STAT3 is persistently activated in a broad range of tumors, where it promotes growth and survival of tumor cells, induces tumor angiogenesis and suppresses anti-tumor immune responses [66] . Abnormal cytokine or growth factor signaling through the Janus kinases (JAK) and receptor tyrosine kinases (RTKs) such as EGFR, led to its aberrant hyper-phosphorylation, and its enhanced activation is often associated with acquired therapeutic resistance to chemotherapy and radiation therapy. Furthermore, STAT3 promotes resistance to targeted EGFR therapies in non-small cell lung carcinoma (NSCLC) and head and neck squamous cell carcinoma (HNSCC) [67, 68] . Because of this position at the center of many converging signaling and oncogenic pathways, STAT3 has become an attractive target for cancer therapy. Several strategies have been developed to target the STAT3 pathway in vivo, including small drug inhibitors, peptide analogs, decoy binding-site oligonucleotides and over-expression of STAT3β, an alternative isoform of STAT3 that acts as a dominant negative/antagonist variant of STAT3 [69, 70] .
The truncated STAT3β isoform is generated from usage of an alternative 3'ss of exon 23, 50 nucleotides downstream of the normal 3'ss [71] . The resulting stop codon causes STAT3β to lack 55 residues of the C-terminal transactivation domain (TAD). STAT3β can still be phosphorylated at the Tyr705 position, essential for dimerization and nuclear translocation, and thus it retains the ability to bind target nuclear DNA sequences as a homo-dimer or heterodimer (with full length STAT3 α, or other transcription factors). As a consequence, STAT3β can act as a dominant negative regulator as well as mediate additional distinctive features that add to the complex STAT3 signaling cascade [70, 72, 73] .
Phosphorodiamidate morpholinos (PMOs) targeting an identified ESE in Exon 23 of STAT3 can quantitatively switch the endogenous mRNA from the alpha to the beta form in multiple cell types (Figure 1c ) [73] . In vitro, antisense modulation of STAT3β/α ratios results in a reduction in cell viability and an increase in apoptosis, higher than those observed in a parallel total STAT3 knockdown experiment [73] . The enhanced biological effect of the alpha to beta switch compared to the knockdown appears to be due to the activation of a unique STAT3β-specific regulation program with antitumorigenic characteristics, rather than a direct block of canonical STAT3 targets. Conjugation of the STAT3β-inducing PMOs to a cell-penetrating dendrimer (vivomorpholinos [74] ) allows redirection of STAT3 splicing in vivo and concomitant tumor regression in a breast cancer xenograft model [73] . Remarkably, under comparable experimental conditions, effective knockdown of STAT3 has no significant effect on tumor growth, underscoring the qualitative difference in reprogramming versus knockdown approaches and the vast, untapped potential of splicing redirection in cancer therapy.
Activation of intronic polyadenylation (IPA): Induction of secreted decoy RTKs
Activation of the RTK signaling pathways represents a key aspect of tumorigenesis in a broad range of human cancers [75, 76] . The targeting of oncogenic RTKs provides a classic example of molecular targeted therapeutic approach in modern cancer therapy. Effective targeted therapies to RTKs include small molecule tyrosine kinase inhibitors and monoclonal antibodies [77] . However, resistance invariably emerges over time, and secondary lines of treatment need to be developed for relapsing patients.
An alternative approach to target RTK receptor pathways has been the delivery of recombinant soluble, dominant-negative RTKs variants (secreted decoy RTKs, sdRTKs) comprising the sole ligand-binding, extracellular domain (ECD), by either direct intravenous administration or using gene-therapy viral expression vectors. SdRTKs antagonize RTK signaling by binding and sequestering the activating ligand and/or by engaging the endogenous receptor in non-productive dimers (Figure 2 ). An example of this approach is Aflibercept, a VEGF trap that suppresses tumor growth and vascularization in vivo and is currently in Phase III clinical trials [78] .
A recent study demonstrated the existence of tens of natural endogenous sdRTKs, which are expressed from most RTK genes, where they are generated by the activation of IPA sites in introns upstream of the transmembrane domain-encoding exons [79] . The controlled and specific induction of such sdRTKs can be obtained by ASO targeting the 5' splice site immediately upstream of an IPA signal [79] . Normally, directing an ASOs to the 5'ss would interfere with splicing, typically resulting in exon skipping. However, if a bona fide PAS is present just downstream in the intron, targeting the 5'ss activates the intronic PAS to generate a truncated mRNA by a U1snRNP-dependent mechanism (Figure 2) .
U1snRNP plays an essential role in pre-mRNA splicing, where it is needed to select and define 5'ss by base-pairing with its own snRNA [80] . In addition, U1snRNP can also directly inhibit polyadenylation when tethered to the 3'UTR of a gene [81, 82] . This suppression by U1 is not limited to the 'normal' 3' UTR, but is in fact a general non-splicing function of U1, possibly as part of the RNA surveillance machinery [79, 83] . Since in any pre-mRNA, every intron 5'ss is bound by U1 during splicing, downstream IPA sites are silenced as a consequence. Hence, preventing U1 binding at the 5'ss would relieve suppression and allows IPA to occur, in a splicing-independent mode.
On the basis of these observations, ASOs were designed to specifically block U1snRNP binding to individual 5'ss sites upstream of the IPA sites corresponding to various natural sdRTKs (EGFR, MET, HER2, VEGFR1 and VEGFR2), resulting in their activation in place of the endogenous full length RTKs [79] . This was exemplified by targeting of VEGFR2, the main mediator of VEGF signaling. Dysregulation of signaling via this receptor is common in tumorigenesis, with mitogenic and angiogenic consequences. Vivomorpholino ASOs were used to induce endogenous sVEGFR2 by IPA activation [79] (Figure 1d ) and to suppress VEGF signaling and angiogenesis in a paracrine and autocrine fashion in vitro and in vivo [79, 84] , reproducing the inhibitory activity of the natural sVEGFR2 variant [85] .
A similar approach has been applied to HER2/ErB2, a member of the EGFR family of receptor kinases, which is over-expressed in many human malignancies and is prevalent in breast cancer [86] . To activate endogenous soluble HER2 receptors, a 2'-MOE ASO was directed against the 5'ss of exon 15 of HER2, inducing exon skipping and leading to a frameshift and the putative use of a premature stop codon upstream of the transmembrane domain [87] . The ASO treatment was associated with an increase in apoptosis and inhibition of proliferation in breast cancer cell lines. Interestingly, intron 15 of HER2 also contains an intronic PAS, which can be activated by targeted PMOs [79] , suggesting that the observed truncated version and associated biology may be generated by IPA activation rather than (or in addition to) NMDescaping exon-skipping.
In general, the generation of sdRTKs is a potent approach to target oncogenic signaling pathways via three potential scenarios (Figure 2 ) that occur simultaneously upon addition of a single ASO compound: 1) concomitant downregulation of full-length oncogenic RTK; 2) secretion of a ligand-binding soluble receptor leading to its sequestration; 3) non-productive dimerization with residual receptors or co-receptors.
The result is a powerful approach that recapitulates, by use of a single compound, the application of multiple inhibitory strategies: knockdown of the gene's expression, trapping of the ligand and trans-inactivation of the receptor, all of which are widely used to block signaling RTK activities in different experimental systems and therapeutic scenarios. Overall, given the essential and central role of aberrant RTK signaling in a broad range of cancers and the existence of sdRTK variants for most of them, ASOmediated activation of IPA and the induction of endogenous antagonistic RTK isoforms holds a tremendous therapeutic potential in cancer therapy.
Conclusion
The application of large scale cancer genome sequencing and molecular profiling has opened the door to tackling cancer through the identification of genes and networks essential to the survival of a tumor and/or its malignant progression. It has also permitted the development of highly specific molecular targeted therapies, traditionally based on small molecule compounds or monoclonal antibodies. Advances in nucleic acid chemistry and pharmacology indicate that antisense-based therapies may finally fulfill their great potential as a bona-fide alternative drug discovery platform to develop novel anti-cancer agents.
